Treatment of Helicobacter pylori

doi:10.3748/wjg.v7.i3.303

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 3

This Article

Reference Citation Analysis (0)

(0)

(4785)

(7)

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Gastroenterol. Jun 15, 2001; 7(3): 303-307
Published online Jun 15, 2001. doi: 10.3748/wjg.v7.i3.303

Table 2 Low dose triple therapy

Therapy	PPI or RBC	PPI or RBC
	Amoxycillin	Clarithromycin
	Clarithromycin	Metronidazole
Dosing	b.d.	b.d.
	1 g b.d.	250 mg b.d.
	500 mg b.d.	400 mg b.d.
Duration		One week
Side effects	Nausea, diarrhoea, taste disturbances
H. pylori eradication	90%	90% in MSS
H. pylori eradication		75% in MRS

PPI: Proton pump inhibitor; RBC: Ranitidine bismuth citrate; b.d.: Twice daily; MSS: Metronidazole-sensitive strain of H. pylori; MRS: Metronidazole-resistant strain of H. pylori

Full Size Table

Citation: Harris A. Treatment of Helicobacter pylori. World J Gastroenterol 2001; 7(3): 303-307
URL: https://www.wjgnet.com/1007-9327/full/v7/i3/303.htm
DOI: https://dx.doi.org/10.3748/wjg.v7.i3.303

Harris A. Treatment of Helicobacter pylori. World J Gastroenterol 2001; 7(3): 303-307 [PMID: 11819780 DOI: 10.3748/wjg.v7.i3.303]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.